Medical News Today4d
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Morningstar2d
MoA Aggressive Allocation Fund
MoA Aggressive Allocation Fund earns a High Process Pillar rating. The most important driver of the rating is its parent firm's superior long-term risk-adjusted performance, as shown by the firm's ...
Medindia3d
FDA Approves Esketamine Nasal Spray for Resistant Depression
The US Food and Drug Administration (FDA) has approved the use of esketamine nasal spray as a standalone treatment for adults with major depressive disorder (MDD) who have not responded adequately ...
WebMD4d
What to Know About the New Nasal Spray for Tough Depression
The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...
pharmaphorum6d
FDA approves Janssen’s ketamine-based nasal antidepressant
Spravato (esketamine) has been touted as a potential blockbuster for Janssen, which faces increasing biosimilar competition from its top-selling rheumatoid arthritis drug Remicade. Estimates from ...
verywellhealth3d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant Depression
The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression. Spravato was ...
greenmarketreport3d
FDA approves J&J’s esketamine as stand-alone depression treatment
The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few years now. Federal regulators approved Johnson & Johnson’s (NYSE: JNJ) nasal ...